Patents by Inventor Tomasz H. Kowalczyk

Tomasz H. Kowalczyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8017577
    Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body. Moreover, counterions such as acetate can protect compacted nucleic acid complexes from adverse effects of lyophilization.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: September 13, 2011
    Assignee: Copernicus Therapeutics, Inc.
    Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
  • Publication number: 20040048787
    Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.
    Type: Application
    Filed: September 8, 2003
    Publication date: March 11, 2004
    Applicant: Copernicus Therapeutics, Inc.
    Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
  • Publication number: 20030171322
    Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.
    Type: Application
    Filed: December 2, 2002
    Publication date: September 11, 2003
    Applicant: Copernicus Therapeutics, Inc.
    Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
  • Publication number: 20030134818
    Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.
    Type: Application
    Filed: December 2, 2002
    Publication date: July 17, 2003
    Applicant: Copernicus Therapeutics, Inc.
    Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
  • Publication number: 20030078229
    Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.
    Type: Application
    Filed: November 27, 2002
    Publication date: April 24, 2003
    Applicant: Copernicus Therapeutics, Inc.
    Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
  • Publication number: 20030078230
    Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.
    Type: Application
    Filed: November 27, 2002
    Publication date: April 24, 2003
    Applicant: Copernicus Therapeutics, Inc.
    Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
  • Patent number: 6506890
    Abstract: An automated nucleic acid compaction device for analyzing and compacting a nucleic acid complex into unimolecular nucleic acid particles. Broadly, the device includes a container support and agitation system; a measuring and testing system; and a dispensing system; all controlled by a control system. The control system controls the support and agitation system and the dispensing system based either on a predetermined formulation or by analysis of feedback data provided by the measuring and testing system. In a preferred embodiment, the device is a real-time measuring and mixing instrument operating in a closed loop system. The preferred embodiment also comprises a monitoring system including a submersible probe which is positioned in the batch solution to provide data to a controller. Once a desired level of nucleic acid compaction is reached, as detected by the monitoring system, the controller stops the dispensing and mixing agitating systems.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 14, 2003
    Inventors: Mark J. Cooper, Tomasz H. Kowalczyk, Murali Krishna Pasumarthy
  • Publication number: 20020042388
    Abstract: Counterions of polycations used to compact nucleic acids profoundly affect shape and stability of particles formed. Shape is associated with differential serum nuclease resistance and colloidal stability. A surrogate for determining such properties that is easy to measure is the turbidity parameter. Shape also affects the suitability and efficacy of compacted nucleic acid complexes for transfecting cells by various routes into a mammalian body.
    Type: Application
    Filed: May 31, 2001
    Publication date: April 11, 2002
    Inventors: Mark J. Cooper, Murali K. Pasumarthy, Tomasz H. Kowalczyk, Maureen Costello
  • Patent number: 6281005
    Abstract: An automated nucleic acid compaction device for analyzing and compacting a nucleic acid complex into unimolecular nucleic acid particles. Broadly, the device includes a container support and agitation system; a measuring and testing system; and a dispensing system; all controlled by a control system. The control system controls the support and agitation system and the dispensing system based either on a predetermined formulation or by analysis of feedback data provided by the measuring and testing system. In a preferred embodiment, the device is a real-time measuring and mixing instrument operating in a closed loop system. The preferred embodiment also comprises a monitoring system including a submersible probe which is positioned in the batch solution to provide data to a controller. Once a desired level of nucleic acid compaction is reached, as detected by the monitoring system, the controller stops the dispensing and mixing agitating systems.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: August 28, 2001
    Assignee: Copernicus Therapeutics, Inc.
    Inventors: Hector L. Casal, Mark J. Cooper, Tomasz H. Kowalczyk, Murali Krishna Pasumarthy, Jose C. Perales, Steven J. Torontali